Evidence map›Paper›PMID 38198097›Full record

ArticleObesity surgery2024

Evaluation of Healthcare Utilisation and Expenditures in Persons with Type 2 Diabetes Undergoing Bariatric-Metabolic Surgery.

Valerie M Monpellier, Rose J Geurten, Ignace M C Janssen, Dirk Ruwaard, Jeroen N Struijs, Peter R van Dijk, Henk J G Bilo, Arianne M J Elissen

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Obesity surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Valerie M MonpellierNederlandse Obesitas Kliniek (Dutch Obesity Clinic), Huis ter Heide, The Netherlands.
Rose J GeurtenDepartment of Health Services Research, CAPHRI Care and Public Health Research Institute, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands. r.geurten@maastrichtuniversity.nl.
Ignace M C JanssenNederlandse Obesitas Kliniek (Dutch Obesity Clinic), Huis ter Heide, The Netherlands.
Dirk RuwaardDepartment of Health Services Research, CAPHRI Care and Public Health Research Institute, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.
Jeroen N StruijsDepartment of Quality of Care and Health Economics, Centre for Nutrition, Prevention and Health Services, National Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
Peter R van DijkDepartment of Endocrinology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
Henk J G BiloDepartment of Internal Medicine, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
Arianne M J ElissenDepartment of Health Services Research, CAPHRI Care and Public Health Research Institute, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.ORCID 0000-0001-9795-8095
Maastricht University · NLNederlandse Obesitas Kliniek · NLUniversity Medical Center Groningen · NLNational Institute for Public Health and the Environment · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeChanges in healthcare utilisation and expenditures after bariatric-metabolic surgery (BMS) for people with type 2 diabetes mellitus (T2DM) are unclear. We used the Dutch national all-payer claims database (APCD) to evaluate utilisation and expenditures in people with T2DM who underwent BMS.

methodsIn this cohort study, patients with T2DM who had BMS in 2016 were identified in the APCD. This group was matched 1:2 to a control group with T2DM who did not undergo BMS based on age, gender and healthcare expenditures. Data on healthcare expenditures and utilisation were collected for 2013-2019.

resultsIn total, 1751 patients were included in the surgery group and 3502 in the control group. After BMS, total median expenditures in the surgery group stabilised (€ 3156 to € 3120) and increased in the control group (€ 3174 to € 3434). Total pharmaceutical expenditures decreased 28% in the surgery group (€957 to €494) and increased 55% in the control group (€605 to €936). In the surgery group, 67.1% did not use medication for T2DM in 2019 compared to 13.3% in the control group. Healthcare use for microvascular complications increased in the control group, but not in the surgery group.

conclusionBMS in people with T2DM stabilises healthcare expenditures and decreases medication use and care use for microvascular complications. In contrast, healthcare use and expenditures in T2DM patients who do not undergo surgery gradually increase over time. Due to the progressive nature of T2DM, it is expected that these differences will become larger in the long-term.

Indexed as

Bariatric SurgeryDiabetes Mellitus, Type 2Obesity, MorbidCohort StudiesHealth ExpendituresHumansPatient Acceptance of Health CareRetrospective StudiesBariatric-metabolic surgeryHealthcare costsHealthcare expendituresHealthcare utilisationMedicationType 2 diabetes mellitus

Identifiers

PMID38198097
PMCPMC10899363
OpenAlexW4390700822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.